- AnaptysBio, Inc. (NASDAQ:ANAB) demonstrates strong capital efficiency, with its Return on Invested Capital (ROIC) significantly higher than its Weighted Average Cost of Capital (WACC).
- The company boasts an ROIC of 14.06% against a WACC of 10.67%, yielding a robust ROIC to WACC ratio of 1.32.
- AnaptysBio, Inc. stands out in the biopharmaceutical sector with a positive ROIC, contrasting with peers that show negative returns on invested capital.
AnaptysBio, Inc. (NASDAQ:ANAB) is a clinical-stage biotechnology company that develops treatments for inflammation and immuno-oncology. A key way to measure its performance is through capital efficiency. This shows how well a company uses its money to generate profits for its shareholders.
We can measure this efficiency by comparing two key metrics. The first is Return on Invested Capital (ROIC), which is the profit a company earns from its investments. The second is the Weighted Average Cost of Capital (WACC), which is the average cost of the funds it uses to operate.
AnaptysBio, Inc. demonstrates strong capital efficiency with an ROIC of 14.06%, which is significantly higher than its WACC of 10.67%. This results in a ROIC to WACC ratio of 1.32. A ratio above one indicates that the company is effectively creating value from the capital it has invested.
This performance stands out when compared to its peers. Competitors like Deciphera Pharmaceuticals (NASDAQ:DCPH) and Crinetics Pharmaceuticals (NASDAQ:CRNX) are also in the biopharmaceutical sector. However, these companies currently show negative returns on their invested capital, a common trait for firms still heavily investing in research.
For example, Deciphera Pharmaceuticals has an ROIC of -55.99% and Kura Oncology (NASDAQ:KURA) has an ROIC of -57.53%. AnaptysBio, Inc. is the only company in this peer group with a positive ROIC that is also higher than its cost of capital. This highlights its strong financial management.
